[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.50.247. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
January 2016

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor

Author Affiliations
  • 1Department of Dermatology, Stanford University School of Medicine, Redwood City, California
  • 2Department of Pathology, Stanford University School of Medicine, Palo Alto, California
  • 3Department of Medicine–Head and Neck Oncology, Stanford University School of Medicine, Stanford, California
JAMA Dermatol. 2016;152(1):106-108. doi:10.1001/jamadermatol.2015.2705

Unresectable cutaneous squamous cell carcinomas (SCCs) can be difficult to treat: only about 30% of patients respond to any type of current treatment.1 Substantial progress has recently been made in the development of immunotherapy for the treatment of cancer. In particular, checkpoint blockade using antibodies that impede immune inhibitory pathways, such as programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1), represents a novel strategy.

First Page Preview View Large
First page PDF preview
First page PDF preview
×